Business Context and Reporting Period
This Form 6-K filing by Can-Fite Biopharma Ltd. covers the month of September 2018, specifically dated September 12, 2018. The registrant is a foreign private issuer based in Petach-Tikva, Israel, filing under Rule 13a-16 of the Securities Exchange Act of 1934.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report serves as a notification of a corporate event rather than a financial statement.
Material Changes
The primary material event reported is the issuance of a press release on September 12, 2018, announcing a poster presentation of pre-clinical data regarding the anti-fibrogenic effects of the company's drug candidate, Namodenosen, in Non-Alcoholic Fatty Liver Disease (NAFLD)/Non-Alcoholic Steatohepatitis (NASH). This presentation occurred at the Hepatic Fibrosis Single Topic Conference of the American Association for the Study of Liver Diseases (AASLD).
Guidance, Outlook, and Risks
The filing incorporates by reference the "Forward Looking Statements" section of the attached press release (Exhibit 99.1) into the company's Registration Statements on Form F-3. No specific financial guidance, management commentary on operations, or detailed risk factors are provided within the body of this specific Form 6-K text.
Investor Verification Checklist
- Review the full text of the press release (Exhibit 99.1) for details on the Namodenosen pre-clinical data.
- Verify the specific findings presented at the AASLD Hepatic Fibrosis Single Topic Conference.
- Check the company's Form F-3 Registration Statements for the incorporated forward-looking statements.
- Confirm the status of the NAFLD/NASH clinical development program in subsequent filings.